Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American College of Rheumatology (ACR) Convergence 2024 meeting, taking place November 14-19, 2024, in Washington, D.C.

Details of the oral presentation are as follows:

Title: ADI-001: An Allogeneic CD20-targeted γδ CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune Indications Session Name: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II Abstract Number: 1866169 Presenting Author: Monica Moreno, Ph.D. Date and Time: November 19, 2024; 12:00 p.m. – 12:15 p.m. ET

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

Adicet Bio., Inc. Investor and Media Contacts

Investors: Anne Bowdidge abowdidge@adicetbio.com

Janhavi Mohite Precision AQ 212-362-1200 janhavi.mohite@precisionaq.com

Media: Kerry Beth Daly kbdaly@adicetbio.com

Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Adicet Bio Charts.
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Adicet Bio Charts.